Get Plus

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

Ongoing Story· Today

Obesity Drug Wegovy Shows Promise in Young Children in New Study

2 developments

HamalHealth

Weight-Loss Drug Wegovy Tested Successfully in Children as Young as Six

Translated & summarized from Hamal by baba

CenterNeutral tone

Hebrew · 1 newsroom

The weight-loss drug Wegovy has demonstrated significant success in a clinical trial for children aged six to twelve with obesity, with nearly 80% achieving a 10% BMI reduction. The trial, conducted by Novo Nordisk, also showed improvements in cardiac and metabolic health markers. While the drug's safety profile appears similar to previous studies, long-term effects are still under investigation. In Israel, the drug is currently approved only for adolescents aged 12 and older.

The story in 5 lines · by baba

  • Wegovy trial shows nearly 80% of children aged 6-12 with obesity achieved 10% BMI reduction.
  • The drug also improved cardiac and metabolic health markers in pediatric participants.
  • Novo Nordisk reported a similar safety profile to previous semaglutide studies.
  • In Israel, Wegovy is approved for adolescents 12 and older, not younger children.
  • Long-term effects and sustained weight loss after treatment cessation require further study.

The weight-loss injection Wegovy, already approved for adults and adolescents, has shown promising results in a clinical trial involving children aged six to under twelve with obesity. According to manufacturer Novo Nordisk, nearly 80% of children receiving the drug achieved at least a 10% reduction in their Body Mass Index (BMI), compared to none in the placebo group. This metric refers to BMI reduction, not necessarily a 10% decrease in body weight.

The STEP Young trial, which involved children with severe obesity at the outset, administered weekly injections of semaglutide, the active ingredient in Wegovy, or a placebo. Both groups also received counseling on reduced-calorie diets and increased physical activity. After 68 weeks, the Wegovy group saw an average BMI decrease of 17.4%, while the placebo group experienced a 2.2% increase.

Further analysis indicated that 38.4% of children in the Wegovy group dropped below the obesity threshold, compared to 2.1% in the placebo group. The drug's safety profile in the trial was similar to previous studies, with no unexpected safety signals regarding growth or sexual development. However, long-term effects and sustained weight loss after treatment cessation require further investigation.

Dr. Anya Gesterboff, Director of the Yale University Obesity Research Center, noted that severe obesity can impact children's health and daily lives, and the treatment also showed improvements in cardiac and metabolic health markers. While these improvements are encouraging, they do not yet confirm the prevention of long-term complications.

In Israel, Wegovy is currently approved for adolescents aged 12 and above under specific conditions, including a weight requirement and accompanying medical and nutritional support. The trial results for younger children do not constitute approval for their use, which awaits regulatory bodies like the FDA.

HamalCentre · Tel Aviv

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

HealthTopic

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

Mentioned

Related stories · 1

Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.

Open the Wire